For isolating GLP-1-only effects, semaglutide alone is the cleaner tool
10.1001/jamaoncol.2016.5688 36 FlowersS
Data availability The data dictionary, the statistical analysis plan, and analytic coding can be made available from the corresponding author upon reasonable request
These are all questions that future research needs to address
BMS is already facing generic-drug incursion in 2022 for Revlimid (lenalidomide), a drug for treating myelodysplastic syndrome, multiple myeloma, and mantle cell lymphoma and will later face generic-drug competition for Eliquis (apixaban), an anticoagulant, for which it is partnered with Pfizer ( see Figure 2)
Any injectable product with unclear licensing, unclear ingredients, or unreliable sourcing raises safety questions